Isotretinoin, pregnancies, abortions and birth defects: a population‐based perspective
Open accessThe DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
What is already known about this subject • As of now, no population‐based data exist on the incidence of pregnancy, elective abortions, and birth defects while on isotretinoin. • From surveys or interventional studies, it is known that pregnancy rates while on isotretinoin are comparable to the baseline rate, and that birth defect rates associated with first‐trimester exposure are 10 times greater than in the general population. • Given that women decide to terminate pregnancies based on the available data, population‐based estimates are needed. What this study adds • This first non‐interventional population‐based study on the risk of pregnancy while being exposed to isotretinoin has shown that the rate of pregnancy is four times greater than what has been published to date (32.7/1000 person‐years). • Any pregnancy while using isotretinoin is the result of a failure of pregnancy prevention strategies, hence, thus far, pregnancy prevention programmes have failed. • The rate of elective abortions is much higher than previously reported (84%). • Women of a lower socio‐economic level and high users of healthcare services are more likely to become pregnant while on isotretinoin, suggesting that high use of health services increase the opportunity of having a prescription for isotretinoin or of having a pregnancy diagnosis. Aims: To estimate the population‐based incidence rates of pregnancy, spontaneous and elective abortions, and birth defects associated with isotretinoin use, and to determine predictors of pregnancy while on isotretinoin. Methods: Using the RAMQ (medical and pharmaceutical data), MED‐ECHO (hospitalizations) and ISQ (births and deaths) databases for the period 1984–2002, a cohort of 8609 women between 13 and 45 years of age and with a first prescription for isotretinoin (date of entry in the cohort) was identified. Women were eligible if they were insured by RAMQ for their medications at least 12 months before entry in the cohort and until 1 month after the end of their isotretinoin treatment. Pregnancies, spontaneous and elective abortions, and birth defects were identified using procedure codes and medical diagnoses. Results: Of the 8609 women included, 90 became pregnant, an annual incident pregnancy rate during isotretinoin treatment of 32.7 per 1000 person‐years of treatment (95% confidence interval 26.6, 40.1). Of the 90 women who became pregnant while on the drug, 76 terminated the pregnancy (84%), three had a spontaneous abortion (3%), two had trauma during delivery resulting in neonatal deaths (2%) and nine had a live birth (10%). Among the live births, only one had a congenital anomaly of the face and neck (11%). Adjusting for potential confounders, predictors of becoming pregnant while on isotretinoin were lower socio‐economic level, one or more visits to the doctor or to the emergency department, or one or more hospitalization while on isotretinoin; concomitant isotretinoin and oral contraceptive use had a preventive effect. Conclusions: This first non‐interventional population‐based study generated incidence rates of pregnancy while on isotretinoin four times greater than what has been reported in the literature thus far; elective abortion rates were also much higher in our study. This shows the importance of using population‐based data for public health purposes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Tamblyn, R., Lavoie, G., Petrella, L., & Monette, J. (1995) · Journal of Clinical Epidemiology · doi:10.1016/0895-4356(94)00234-h · Cited by 577
Epidemiology of isotretinoin exposure during pregnancy
Dai, W. S., LaBraico, J. M., & Stern, R. S. (1992) · Journal of the American Academy of Dermatology · doi:10.1016/0190-9622(92)70088-w · Cited by 133
Cited by
Safety of dermatologic medications in pregnancy and lactation
Murase, J. E., Heller, M. M., & Butler, D. C. (2014) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2013.09.010 · Cited by 220
Valuck, R. J., Orton, H. D., & Libby, A. M. (2009) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.08m04943 · Cited by 106
“Pregnancy was noted for any female patient in the observation period using ICD-9 codes and pregnancy-related procedure codes.(14) The following psychiatric disorders were included as indicator variables: bipolar disorder, schizophrenia, anxiety spectrum, substance use disorder, and other mental health problem.”
MethodRademaker, M., Wishart, J. M., & Birchall, N. M. (2014) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.12170 · Cited by 58
Metadata
- Authors
- Bérard, A., Azoulay, L., Koren, G., Blais, L., Perreault, S., & Oraichi, D.
- Venue
- British Journal of Clinical Pharmacology
- Publisher
- Wiley
- Published
- 2007-01-03
- Volume
- 63
- Issue
- 2
- Pages
- 196-205
- ISSN
- 0306-5251 (ISSN-L)
- 1365-2125
- OpenAlex
- W1994051922
- Cited by
- 113
- References
- 2
- FWCI
- 10.56
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.